Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Vancive Medical Technologies™, CareFusion Sign Agreement for Antimicrobial Dressing



  Vancive Medical Technologies™, CareFusion Sign Agreement for Antimicrobial
  Dressing

   Exclusive agreement in North America marks first line of vascular access
                          dressings from CareFusion

Business Wire

CHICAGO -- November 19, 2013

Vancive Medical Technologies™ and CareFusion Corporation (NYSE:CFN) today
announced an exclusive agreement in the United States, Canada and Mexico for
the licensing and distribution of Vancive’s BeneHold™ Chlorhexidine Gluconate
(CHG) antimicrobial Adhesive Technology for applications in vascular access.

Under the agreement, CareFusion will market Vancive’s unique antimicrobial
adhesive technology used with transparent dressings that are ideally suited
for protection of catheter insertion sites. The first product received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) in September 2012
and will be co-branded under CareFusion’s new ChloraShield™ brand.

“We are excited about this collaboration, and believe it is an excellent
opportunity to combine the unique capabilities of each company,” said Howard
Kelly, president and general manager of Vancive Medical Technologies. “By
bringing together the considerable infection prevention expertise at
CareFusion and Vancive’s cutting-edge technologies, we will provide innovative
solutions to the vascular access market.”

CareFusion and Vancive are working together to develop a comprehensive line of
dressing products that incorporate the BeneHold™ CHG antimicrobial Adhesive
Technology to meet the specific needs associated with many types of vascular
access procedures. CareFusion expects to commercialize these offerings during
the company’s fiscal third quarter, which begins in April.

“The collaboration with Vancive Medical Technologies and the new ChloraShield™
line of dressings are a perfect fit with our leadership in CHG products,” said
Jim Leitl, senior vice president and general manager of Medical Specialties at
CareFusion. “These innovative vascular access dressings extend our clinically
differentiated infection prevention and vascular access product portfolios,
allowing us to create greater value for our customers.”

BeneHold is a trademark of Avery Dennison Corporation. ChloraShield is a
trademark of CareFusion Corporation.

About Vancive Medical Technologies

Vancive Medical Technologies makes inspired advances that lead to intelligent
results. The business uses the most advanced adhesive and material
technologies to create products that make healthcare easier for everyone.
Vancive Medical Technologies is an Avery Dennison business headquartered in
Chicago, Illinois. To learn more about Vancive Medical Technologies, visit
www.vancive.averydennison.com.

About Avery Dennison

Avery Dennison (NYSE:AVY) is a global leader in labeling and packaging
materials and solutions. The company’s applications and technologies are an
integral part of products used in every major market and industry. With
operations in more than 50 countries and 30,000 employees worldwide, Avery
Dennison serves customers with insights and innovations that help make brands
more inspiring and the world more intelligent. Headquartered in Pasadena,
California, the company reported sales from continuing operations of $6
billion in 2012. Learn more at www.averydennison.com.

About CareFusion

CareFusion (NYSE:CFN) is a global corporation serving the health care industry
with products and services that help hospitals measurably improve the safety
and quality of care. The company develops industry-leading technologies
including Alaris^® infusion pumps, Pyxis^® automated dispensing and patient
identification systems, AVEA^®, AirLife^® and LTV^® series ventilation and
respiratory products, ChloraPrep^® products, MedMined^® services for data
mining surveillance, V. Mueller^® surgical instruments, and an extensive line
of products that support interventional medicine. CareFusion employs
approximately 15,000 people across its global operations. More information may
be found at www.carefusion.com.

Contact:

Vancive Media Contact
Bob Giuliano
T: +1 610-328-1051
Bob.Giuliano@prplace.biz
or
Vancive Marketing Communications Contact
Suzanne Kelly
T: + 1 312-629-4607
Suzanne.kelly@averydennison.com
or
CareFusion Media Contact
Troy Kirkpatrick
T: +1 858-617-2361
troy.kirkpatrick@carefusion.com
or
CareFusion Investor Contact
Jim Mazzola
T: +1 858-617-1203
jim.mazzola@carefusion.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement